Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: Results from the global utilization of streptokinase and t-PA for occluded coronary arteries (GUSTO) III trial

Circulation

Volumn 102, Issue 15, 2000, Pages 1761-1765

  Topol, Eric J ^a   Ohman, E Magnus ^b   Armstrong, Paul W ^c   Wilcox, Robert ^d   Skene, Alan M ^e   Aylward, Philip ^f   Simes, John ^g   Dalby, Anthony ^h   Betriu, Amadeo ⁱ   Bode, Christoph ^j   White, Harvey D ^k   Hochman, Judith S ^l   Emanuelson, Hakan ^m   Vahanian, Alec ⁿ   Sapp, Shelly ^a   Stebbins, Amanda ^b   Moliterno, David J ^a   Califf, Robert M ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e Nottingham Clinical Trial Data Centre   (United Kingdom)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h MILPARK HOSPITAL   (South Africa)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k GREEN LANE HOSPITAL   (New Zealand)

^l ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^m ASTRAZENECA   (United Kingdom)

ⁿ BICHAT HOSPITAL   (France)

more..

Author keywords

Myocardial infarction; Plasminogen activators; Reperfusion

Indexed keywords

ALTEPLASE; PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0034633819     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.15.1761     Document Type: Article

References (14)

1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
2. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of acute myocardial infarction
3. Angio Scandinavian Study of Early Thrombolysis (ASSET): Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction
4. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
5. An international, multicenter, randomized comparison of reteplase with alteplase for acute myocardial infarction
6. Equivalence trials
7. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravivenza nell'Infarto-1 study
8. ISIS-2: 10-Year survival among patients with suspected acute myocardial infarction in randomized comparison of intravenous streptokinase, oral aspirin, both, or neither
9. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction
10. One-year results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-I) Trial
11. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment: The GUSTO III platelet study
12. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase
13. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial
14. Claims of equivalence in medical research: Are they supported by the evidence?